BioNTech Inks Cancer-Focused Deal Success

BioNTech Inks Cancer-Focused Deal Success

Post Covid-19 Vaccine, BioNTech Inks Cancer-Focused Deal Success

BioNTech SE is the Company behind one of the most broadly used vaccines against Covid-19. In a deal intended to strengthen its business of developing cutting-edge cancer therapies, they agreed to take a U.S. manufacturing plant from Kite.

The deal primarily focuses on Kite’s research and development, as well as manufacturing activities relating to its T-cell receptor cell therapy. This is an experimental model of cancer treatment. BioNTech stated it might acquire Kite’s platform for the research and development of neoantigen TCR cell therapy. This manufacturing facility includes around 50 employees in Md, Gaithersburg. However, the companies have not yet disclosed their financial terms.

BioNTech became famous for the Covid-19 vaccine made with Pfizer Inc, the first shot approved for use in Europe and the U.S. However, their primary focus before the pandemic was on developing personalized cancer therapies.

More specifically, in their trials, they were investigating the body’s immune system to fight tumours. These vaccines are linked to genetic material containing essential proteins related to the virus or cancer cell.

About BioNTech

BioTech stands for Biopharmaceutical New Technologies, a next-generation immunotherapy company establishing novel therapies for cancer and other severe diseases.

The Company uses a broad type of therapeutic drug platforms coupled with computational discovery to promote rapid development of novel biopharmaceuticals.

Its comprehensive portfolio of oncology products combines individualized mRNA-based therapies, bispecific checkpoint immuno-modulators, innovative chimeric antigen receptor T cells. All of these products specifically target small molecules and cancer antibodies. Based on its experience in in-house manufacturing capabilities and mRNA vaccine development, BioNTech with its collaborators is developing various mRNA vaccine candidates for a variety of infectious diseases with its diverse oncology pipeline. BioNTech established a widespread set of relationships with many global pharmaceutical collaborators. In fact, this list has some of the biggest names in pharmaceuticals. These include Bayer Animal Health, Genmab, Sanofi, Genentech, Regeneron, Fosun Pharma and Pfizer.

The post BioNTech Inks Cancer-Focused Deal Success appeared first on FinanceBrokerage.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © 2019 Billionaire Club Co LLC. All rights reserved

Loading the chat ...